|
Academic/Biomedical Research
News & Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Company Profiles
Research Store
Research Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
9/13/2006 12:19:35 PM
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Sept. 13, 2006--Andrx Corporation (Nasdaq:ADRX) ("Andrx" or the "Company") announced today that on September 12, 2006, it certified that each representation and warranty of the Company contained in the merger agreement, as amended, with Watson Pharmaceuticals, Inc. (NYSE:WPI) is true and correct as of September 12, 2006, except as would not have individually or in the aggregate, a material adverse effect and that no material adverse effect has occurred with regard to Andrx or its ability to consummate the merger since March 12, 2006. The merger agreement, as amended, provides that in the event that the representations and warranties made by Andrx in the merger agreement are true and correct on September 12, 2006, then such representations and warranties will be deemed to be true on all dates subsequent to September 12, 2006. In addition, in the event that no material adverse effect has occurred with regard to Andrx or its ability to consummate the merger on September 12, 2006, then if a material adverse effect were to occur after September 12, 2006, such material adverse effect will not affect the consummation of the merger.
|
|
|
|
|
|
|
|
|
|
|